← Human Trials & Peer-Reviewed Studies
Effect of growth hormone treatment on adult height in peripubertal children with idiopathic short stature: a randomized, double-blind, placebo-controlled trial.
Plain-language guide to PMID 15240584 (2004): double-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 33 patients.
Key Facts
- PMID
- 15240584
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 2004
- Study type
- Randomized Controlled Trial
- Authors
- Leschek EW et al. (12 authors)
- DOI
- 10.1210/jc.2003-031457
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.
The researchers performed a randomized, double-blind, placebo-controlled trial to determine the effect of GH on adult height in peripubertal children.
Why It Was Studied
At study termination, adult height measurements were available for 33 patients after mean treatment duration of 4.4 yr.
Who Took Part
The study group was 33 patients.
PubMed indexes the participants as children and teenagers, both men and women.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Neither the patients nor the staff measuring them knew who was on Exogenous HGH, sermorelin & older GHRPs (why they're passed over), so expectations could not easily colour the readings.
A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.
What Was Measured
At study termination, adult height measurements were available for 33 patients after mean treatment duration of 4.4 yr.
Topics PubMed links to this paper include Body Height, Growth Disorders, Human Growth Hormone and Puberty.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 33 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2004 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.